View Older Stories View More Recent Stories

Aug 30, 2023 04:05PM Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Aug 14, 2023 04:05PM Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 2, 2023 04:05PM Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview
Aug 1, 2023 07:30PM Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 24, 2023 04:07PM Acadia Pharma (ACAD) Appoints Kevin R. Oliver as SVP and Chief Business Officer
Jul 24, 2023 04:05PM Acadia Pharmaceuticals Appoints Kevin R. Oliver, Ph.D., as Senior Vice President, Chief Business Officer
Jul 19, 2023 04:04PM Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 2, 2023
Jul 13, 2023 04:06PM Acadia Pharma (ACAD) Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrom
Jul 13, 2023 04:05PM Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome
Jun 26, 2023 05:00PM Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 13, 2023 04:05PM Acadia Pharma (ACAD) Announces Phase 3 Development Candidate ACP-101 for Prader-Willi Syndrome
Jun 13, 2023 04:05PM Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (intranasal carbetocin) for Prader-Willi Syndrome
Jun 8, 2023 11:15AM Acadia Pharma (ACAD) Announces Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER Study Evaluating DAYBUE in Patients with Rett Syndrome
Jun 8, 2023 11:10AM Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER™ Study Evaluating DAYBUE™ (trofinetide) Efficacy and Safety in Patients with Rett Syndrome
Jun 1, 2023 09:04AM Acadia Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
May 8, 2023 04:05PM Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview
May 5, 2023 04:04PM Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 2, 2023 09:04AM Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
Apr 25, 2023 09:04AM Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2023
Apr 20, 2023 09:04AM Acadia Pharmaceuticals to Present DAYBUE™ (trofinetide) Clinical Data and Rett Syndrome Real World Evidence at the 2023 American Academy of Neurology (AAN) Annual Meeting
Apr 17, 2023 09:04AM Acadia Pharma (ACAD) Announces DAYBUE is Now Available for the Treatment of Rett Syndrome
Apr 17, 2023 09:04AM Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome
Apr 11, 2023 09:04AM Acadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
Mar 13, 2023 05:50AM Acadia Pharma (ACAD) Announces FDA Approval of DAYBUE
Mar 10, 2023 09:45PM Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older
Feb 27, 2023 04:05PM Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview
Feb 14, 2023 04:05PM Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
Feb 13, 2023 04:15PM Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 9, 2023 09:00AM Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development
Jan 3, 2023 09:05AM Acadia Pharma (ACAD) Reports Retrospective Analysis Showing Lower All-Cause Mortality Risk Among Parkinson’s Disease Psychosis Patients Treated with NUPLAZID
Jan 3, 2023 09:00AM Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson’s Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other
Dec 21, 2022 04:05PM Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
Nov 8, 2022 04:05PM Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Nov 2, 2022 04:05PM Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results
Oct 27, 2022 04:34PM Acadia Pharma (ACAD) Announces Planned Retirement of President Srdjan (Serge) Stankovic
Oct 27, 2022 04:05PM Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) Stankovic
Oct 20, 2022 04:05PM Acadia Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022
Oct 13, 2022 07:31AM Acadia Pharma (ACAD) Appoints Adora Ndu to its Board
Oct 13, 2022 07:30AM Acadia Pharmaceuticals Appoints Adora Ndu, Pharm.D., J.D. to its Board of Directors
Oct 4, 2022 07:30AM Acadia Pharmaceuticals Recognizes Rett Syndrome Awareness Month and Launches New Awareness Campaign, Rett Revealed
Sep 12, 2022 07:30AM Acadia Pharma (ACAD) Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepted for Filing and Review by U.S. FDA
Sep 12, 2022 07:30AM Acadia Pharmaceuticals Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepted for Filing and Review by U.S. FDA
Sep 1, 2022 09:03AM Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
Aug 8, 2022 04:05PM Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results
Aug 4, 2022 11:05PM Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheime
Jul 25, 2022 04:05PM Acadia Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 8, 2022
Jul 18, 2022 04:07PM Acadia Pharma (ACAD) Submits NDA U.S. FDA for Trofinetide for the Treatment of Rett Syndrome
Jul 18, 2022 04:07PM Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome
Jun 21, 2022 06:30AM Acadia Pharma (ACAD) Said FDA Panel Voted Against Efficacy of NUPLAZID to Treat ADP
Jun 17, 2022 08:00PM Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis
View More Recent Stories View Older Stories